title: The Clinical Status of Stem Cell Therapy for Ischemic Cardiomyopathy.
abstract: Ischemic cardiomyopathy (ICM) is becoming a leading cause of morbidity and mortality in the whole world. Stem cell-based therapy is emerging as a promising option for treatment of ICM. Several stem cell types including cardiac-derived stem cells (CSCs), bone marrow-derived stem cells, mesenchymal stem cells (MSCs), skeletal myoblasts (SMs), and CD34(+) and CD 133(+) stem cells have been applied in clinical researches. The clinical effect produced by stem cell administration in ICM mainly depends on the transdifferentiation and paracrine effect. One important issue is that low survival and residential rate of transferred stem cells in the infracted myocardium blocks the effective advances in cardiac improvement. Many other factors associated with the efficacy of cell replacement therapy for ICM mainly including the route of delivery, the type and number of stem cell infusion, the timing of injection, patient's physical condition, the particular microenvironment onto which the cells are delivered, and clinical condition remain to be addressed. Here we provide an overview of the pros and cons of these transferred cells and discuss the current state of their therapeutic potential. We believe that stem cell translation will be an ideal option for patients following ischemic heart disease in the future.
authors.affiliation: Cell Therapy Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.
authors.forename: Xianyun
authors.initials: X
authors.lastname: Wang
authors.affiliation: Cell Therapy Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Cell Therapy Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.
authors.forename: Fan
authors.initials: F
authors.lastname: Zhang
authors.affiliation: Cell Therapy Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China ; Department of Immunology, Basic Medical College, Hebei Medical University, Shijiazhuang, Hebei 050017, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China.
authors.forename: Yaqi
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China.
authors.forename: Zirui
authors.initials: Z
authors.lastname: Tan
authors.affiliation: School of Nursing, Hebei Medical University, Shijiazhuang, Hebei 050000, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Hu
authors.affiliation: Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China.
authors.forename: Yixin
authors.initials: Y
authors.lastname: Qi
authors.affiliation: Cell Therapy Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China ; Department of Immunology, Basic Medical College, Hebei Medical University, Shijiazhuang, Hebei 050017, China.
authors.forename: Quanhai
authors.identifier: 0000-0003-3629-3856
authors.initials: Q
authors.lastname: Li
authors.affiliation: Cell Therapy Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.
authors.forename: Baoyong
authors.initials: B
authors.lastname: Yan